BofA update shows where active managers are putting money
Investing.com - Truist Securities maintained its Buy rating and $18.00 price target on Chemours (NYSE:CC) following the company’s second-quarter earnings report. The stock, currently trading at $12.24, has experienced a significant 32.65% decline over the past six months, according to InvestingPro data.
The chemical company’s third-quarter and full-year EBITDA guidance came in below Street expectations, primarily due to operational headwinds in its Titanium Technologies (TT) and Advanced Performance Materials (APM) segments. The company’s current EBITDA stands at $376 million, with a market capitalization of $1.84 billion.
Despite these challenges, Truist noted that Chemours is experiencing stronger-than-expected performance in its Thermal & Specialized Solutions (TSS) segment, driven by continued adoption of its Opteon products.
The research firm characterized the operational issues affecting the TT and APM segments as "short-term in nature" and highlighted the recently announced New Jersey settlement as providing "incremental clarity on the blueprint for resolving legacy PFAS liabilities."
Truist expects Chemours to achieve "significant earnings growth" in 2026 as TSS growth continues and turnaround efforts improve performance in the company’s more cyclical businesses, particularly Titanium Technologies.
In other recent news, Chemours Co reported its financial results for the second quarter of 2025, exceeding analyst expectations. The company achieved an earnings per share (EPS) of $0.58, which was notably higher than the projected $0.46. This represents a 26.09% surprise in EPS. Additionally, Chemours reported revenue of $1.62 billion, surpassing the anticipated $1.56 billion. These results highlight the company’s strong performance during the quarter. There were no reports of mergers or acquisitions involving Chemours. Analyst ratings and other company news were not mentioned in the recent updates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.